Improvements in drugs will prompt the psoriasis market to rise from $6.6 billion in 2014 to more than $13.3 billion by 2024, according to research from GlobalData. 16 April 2016
US company Diplomat Pharmacy has been selected by pharma major Eli Lilly to distribute Taltz (ixekizumab) for the treatment of adults with moderate-to-severe plaque psoriasis. 5 April 2016
French pharma giant Sanofi and the US’s Regeneron Pharmaceuticals have announced positive results for two Phase III studies of dupilumab in patients with moderate-to-severe atopic dermatitis (AD) patients. 1 April 2016
Irish company Fastnet Equity, which last year announced a switch of focus from oil exploration to pharmaceuticals, is seeking to complete a £29.6 million takeover of orphan drug development firm Amryt Pharmaceuticals. 31 March 2016
US biopharma company XenoPort has entered into a license agreement under which Indian drug major Dr Reddy’s Laboratories will be granted exclusive US rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829. 29 March 2016
Chugai Pharmaceutical said on Friday that it has won a lawsuit against companies who by the decision must now stop manufacturing and marketing their generic drugs in infringement of the process patent (Patent No 3310301) on Oxarol (maxacalcitol) Ointment. 26 March 2016
The US Food and Drug Administration (FDA) has approved Eli Lilly’s monoclonal antibody Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis, it has been announced. 23 March 2016
Commenting on the news last week of the $595 million upfront deal between AbbVie and Boehringer Ingelheim, giving rights to AbbVie to develop a psoriasis drug candidate, Bloomberg points out the treatment is aimed at entering a crowded field that includes Humira, AbbVie’s top product with $14 billion in fiscal 2015 sales. 13 March 2016
AbbVie and Boehringer Ingelheim have signed a global collaboration to develop and commercialize BI 655066, an anti-interleukin (IL)-23 monoclonal biologic antibody in Phase III development for psoriasis. 7 March 2016
Novartis has published data showing Cosentyx (secukinumab) remains better than Janssen's Stelara (ustekinumab) in achieving sustained skin clearance at 52 weeks for adults with moderate-to-severe psoriasis. 7 March 2016
Spain’s leading drugmaker Almirall discussed its strategy with The Pharma Letter’s local correspondent, explaining why it has moved out of the respiratory sector to focus on dermatology. 23 February 2016
Mid-sized Japanese drugmaker Otsuka Pharmaceutical has inked a licensing deal with independent US drugmaker Medimetriks Pharmaceuticals, granting Medimetriks exclusive development and commercialization rights for OPA-15406 in the USA and Puerto Rico. 9 February 2016
French independent pharma company Pierre Fabre today announced the launch of a new fund to accelerate the clinical development of new products in oncology and dermatology. 3 February 2016
Almirall says it has exercised a call option to acquire 100% of the share capital of ThermiGen, a privately held USA-based medical aesthetics technology company and a developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications. 1 February 2016
The US Food and Drug Administration has approved Swiss pharma giant Novartis’ Cosentyx (secukinumab) for the treatment of two new indications - adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). 18 January 2016
Allergan yesterday announced that it has acquired Anterios, a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. 8 January 2016
India-based Vyome Biosciences, on Thursday said the US Food and Drug Administration has accepted its Investigational New Drug (IND) application for its lead program VB 1953, a topical therapeutic candidate to treat acne. 7 January 2016
The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024